Exelixis Inc (EXEL)vsVertex Pharmaceuticals Inc (VRTX)
EXEL
Exelixis Inc
$56.21
+0.16%
HEALTHCARE · Cap: $14.62B
VRTX
Vertex Pharmaceuticals Inc
$519.51
+0.79%
HEALTHCARE · Cap: $130.56B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 417% more annual revenue ($12.59B vs $2.44B). EXEL leads profitability with a 35.3% profit margin vs 35.0%. VRTX appears more attractively valued with a PEG of 1.89. EXEL earns a higher WallStSmart Score of 70/100 (B-).
EXEL
Strong Buy70
out of 100
Grade: B-
VRTX
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+64.9%
Fair Value
$164.33
Current Price
$56.21
$108.12 discount
Margin of Safety
+46.5%
Fair Value
$963.47
Current Price
$519.51
$443.96 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 47 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 39.5%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Earnings expanding 26.2% YoY
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
Expensive relative to growth rate
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : EXEL
The strongest argument for EXEL centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 35.3% and operating margin at 39.5%. Revenue growth of 10.6% demonstrates continued momentum.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Debt/Equity. Profitability is solid with margins at 35.0% and operating margin at 38.1%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : EXEL
The primary concerns for EXEL are PEG Ratio.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
EXEL carries more volatility with a beta of 0.42 — expect wider price swings.
VRTX is growing revenue faster at 12.5% — sustainability is the question.
VRTX generates stronger free cash flow (1.0B), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
EXEL scores higher overall (70/100 vs 64/100), backed by strong 35.3% margins and 10.6% revenue growth. VRTX offers better value entry with a 46.5% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Exelixis Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development, and commercialization of new drugs to treat cancers in the United States. The company is headquartered in Alameda, California.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?